Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0262471 (
ENT
)
5,307
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Otalgia is a common symptom in general practice and represents the sensation of pain in the ear. In four patients, three women aged 63, 57 and 37 years, and a man aged 64 years, ear pain was found to be caused by laryngeal carcinoma (two patients), oropharyngeal carcinoma and nasopharyngeal carcinoma (in a Turkish patient). Referred otalgia is an earache that is caused by a nonotologic source. In many cases it is difficult to identify the underlaying disease of referred otalgia. It may be the first symptom of a head-and-neck carcinoma. In case of otalgia with normal otologic findings, the differential diagnostic process must be specifically directed to the common sensory innervation of the ear and the head-and-neck structures. By carefully taking the patient's history with special attention to epidemiological factors such as smoking and drinking habits, racial traits, a positive family history of head-and-neck neoplasms and accompanying complaints and by performing repeated
ENT
examination including advanced imaging techniques, long delay in diagnosing head-and-
neck cancer
can be prevented.
...
PMID:[Referred earache; an important symptom of head-and-neck cancers]. 1002 59
Implementation of daily kilovoltage imaging for setup verification improves the reproducibility of treatment by eliminating small random setup errors. We evaluate the dosimetric consequences of such shifts, not yet evaluated, in a group of head-and-
neck cancer
patients (
ENT
) treated with intensity modulated radiation therapy (IMRT) at Emory University. Twelve patients with
ENT
malignancies were analyzed. On-Board Imaging (OBI) was used in at least 70% of each patient's treatment sessions. An isodose distribution was generated for each fraction, with the isocenter shifted to its calculated location prior to OBI repositioning. These plans were summed and then compared to the simulation plan for coverage of target structures. For these 12 patients, there were a total of 18 planning target volumes (PTV). The mean (range) percent reduction in minimum dose was 12.1% (-1.0 to 43.3). For 10 right necks and 9 left necks treated, the mean percent reduction in minimum dose was 11.8% (-0.6 to 39.7) and 13.3% (-3.6 to 31.2), respectively. The mean reduction in mean dose to the PTV was 1.3% (0 to 5.1). The mean reduction in mean dose to the right and left necks was 1.0% (0.2 to 3.9) and 1.13% (0.4 to 3.4), respectively. From this analysis, we conclude that the shifts made were small and random, with essentially no change in mean dose delivered to target structures. There is, however, significant improvement in the minimum dose delivered. Underdosing even a small portion of the tumor potentially sacrifices the probability of local control; correcting these setup errors seems desirable.
...
PMID:Quantification of dosimetric impact of implementation of on-board imaging (OBI) for IMRT treatment of head-and-neck malignancies. 1798 Aug 30